Related Experiment Video

Updated: Feb 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

429

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer

Idoroenyi Amanam1, Rohan Gupta1, Isa Mambetsariev1

  • 1City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Research Therapeutics, 1500 E Duarte Road, Duarte, CA 91010, USA.

Future Oncology (London, England)
|February 17, 2018
PubMed

Insights

Brigatinib shows promising results for advanced non-small-cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangements. This next-generation ALK inhibitor offers significant response rates and progression-free survival, even in previously treated patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Non-small-cell lung cancer (NSCLC) accounts for 85% of cases.
  • Anaplastic lymphoma kinase (ALK) driver mutations are key in certain NSCLCs.

Purpose of the Study:

  • To evaluate the efficacy of brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor.
  • To assess brigatinib's activity in ALK-rearranged NSCLC patients, including those previously treated with crizotinib.
  • To investigate brigatinib in ALK inhibitor-naive patients through the ALTA-1L Phase III trial.

Main Methods:

  • Clinical trial data analysis from the ALTA study.
  • Assessment of response rates (overall and intracranial) and progression-free survival.
  • Ongoing randomized Phase III trial (ALTA-1L) in treatment-naive patients.

Main Results:

  • Brigatinib demonstrated response rates of 42-50% in previously crizotinib-treated patients.
  • Intracranial response rates ranged from 42-67%.
  • Median progression-free survival was 9.2-12.9 months in this cohort.

Conclusions:

  • Brigatinib exhibits significant efficacy in advanced ALK-rearranged NSCLC.
  • It represents a promising therapeutic option, particularly for patients progressing on or intolerant to crizotinib.
  • Further evaluation in treatment-naive populations is ongoing via the ALTA-1L trial.
Keywords:
ALKALTAEML4–ALK rearrangementNSCLCalectinibbrigatinibcentral nervous system metastasesceritinibcrizotiniblung cancer

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.5K
Position-effect Variegation02:32

Position-effect Variegation

In 1928, a German botanist Emil Heitz observed the moss nuclei with a DNA binding dye. He observed that while some chromatin regions decondense and spread out in the interphase nucleus, others do not. He termed them euchromatin and heterochromatin, respectively. He proposed that the heterochromatin regions reflect a functionally inactive state of the genome. It was later confirmed that heterochromatin is transcriptionally repressed, and euchromatin is transcriptionally active chromatin.
7.1K
Chromatin Position Affects Gene Expression02:35

Chromatin Position Affects Gene Expression

Chromatin is the massive complex of DNA and proteins packaged inside the nucleus. The complexity of chromatin folding and how it is packaged inside the nucleus greatly influences  access to genetic information. Generally, the nucleus' periphery is considered transcriptionally repressive, while the cell's interior is considered a transcriptionally active area. 
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
25.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K